271 related articles for article (PubMed ID: 28950269)
1. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
2. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
González-Calle V; Slack A; Keane N; Luft S; Pearce KE; Ketterling RP; Jain T; Chirackal S; Reeder C; Mikhael J; Noel P; Mayo A; Adams RH; Ahmann G; Braggio E; Stewart AK; Bergsagel PL; Van Wier SA; Fonseca R
Ann Hematol; 2018 Aug; 97(8):1453-1462. PubMed ID: 29623394
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Cho H; Yoon DH; Lee JB; Kim SY; Moon JH; Do YR; Lee JH; Park Y; Lee HS; Eom HS; Shin HJ; Min CK; Kim JS; Jo JC; Kang HJ; Mun YC; Lee WS; Lee JJ; Suh C; Kim K;
Am J Hematol; 2017 Dec; 92(12):1280-1286. PubMed ID: 28833417
[TBL] [Abstract][Full Text] [Related]
5. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Scott EC; Hari P; Kumar S; Fraser R; Davila O; Shah N; Gale RP; Diaz MA; Agrawal V; Cornell RF; Ganguly S; Akpek G; Freytes C; Hashmi S; Malek E; Kamble RT; Lazarus H; Solh M; Usmani SZ; Kanate AS; Saad A; Chhabra S; Gergis U; Cerny J; Kyle RA; Lee C; Kindwall-Keller T; Assal A; Hildebrandt GC; Holmberg L; Maziarz RT; Nishihori T; Seo S; Kumar S; Mark T; D'Souza A
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2443-2449. PubMed ID: 30142419
[TBL] [Abstract][Full Text] [Related]
6. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
Iriuchishima H; Saitoh T; Handa H; Isoda A; Matsumoto M; Sawamura M; Iwasaki A; Ushie C; Hattori H; Sasaki Y; Mitsui T; Yokohama A; Tsukamoto N; Murakami H; Nojima Y
Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
[TBL] [Abstract][Full Text] [Related]
7. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Gopalakrishnan S; D'Souza A; Scott E; Fraser R; Davila O; Shah N; Gale RP; Kamble R; Diaz MA; Lazarus HM; Savani BN; Hildebrandt GC; Solh M; Freytes CO; Lee C; Kyle RA; Usmani SZ; Ganguly S; Assal A; Berdeja J; Kanate AS; Dhakal B; Meehan K; Kindwall-Keller T; Saad A; Locke F; Seo S; Nishihori T; Gergis U; Gasparetto C; Mark T; Nieto Y; Kumar S; Hari P
Biol Blood Marrow Transplant; 2019 Apr; 25(4):683-688. PubMed ID: 30579965
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
9. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E; Terpos E; Roussou M; Gavriatopoulou M; Migkou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas D; Panagiotidis I; Kafantari E; Giannouli S; Zomas A; Konstantopoulos K; Dimopoulos MA
Haematologica; 2017 Mar; 102(3):593-599. PubMed ID: 27789676
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
[TBL] [Abstract][Full Text] [Related]
13. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Romano A; Parrinello NL; Consoli ML; Marchionni L; Forte S; Conticello C; Pompa A; Corso A; Milone G; Di Raimondo F; Borrello I
Ann Hematol; 2015 Nov; 94(11):1875-83. PubMed ID: 26223359
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
Zhou HX; Jian Y; Du J; Liu JR; Zhang ZY; Geng CY; Yang GZ; Wang GR; Fu WJ; Li J; Chen WM; Gao W
Zhonghua Nei Ke Za Zhi; 2024 Jan; 63(1):81-88. PubMed ID: 38186122
[No Abstract] [Full Text] [Related]
16. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma: Experience of an institute in limited resource setting.
Jacob LA; Suresh Babu MC; Lakshmaiah KC; Babu KG; Lokanatha D; Rajeev LK; Lokesh KN; Rudresha AH; Agarwal A; Garg S
Indian J Cancer; 2017; 54(1):340-342. PubMed ID: 29199718
[TBL] [Abstract][Full Text] [Related]
18. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Kuroda J; Shimura Y; Ohta K; Tanaka H; Shibayama H; Kosugi S; Fuchida S; Kobayashi M; Kaneko H; Uoshima N; Ishii K; Nomura S; Taniwaki M; Takaori-Kondo A; Shimazaki C; Tsudo M; Hino M; Matsumura I; Kanakura Y;
Int J Hematol; 2014 Apr; 99(4):441-9. PubMed ID: 24584872
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
Mihou D; Katodritou E; Zervas K
Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
[TBL] [Abstract][Full Text] [Related]
20. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
Hari PN; Zhang MJ; Roy V; Pérez WS; Bashey A; To LB; Elfenbein G; Freytes CO; Gale RP; Gibson J; Kyle RA; Lazarus HM; McCarthy PL; Milone GA; Pavlovsky S; Reece DE; Schiller G; Vela-Ojeda J; Weisdorf D; Vesole D
Leukemia; 2009 Aug; 23(8):1528-34. PubMed ID: 19322205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]